Advanz Zeroes In On Innovative Assets And M&A
Business Has Increased In Value To Around €670m
Advanz has identified three key spaces in which it is seeking to generate value: innovative assets, M&A and existing commercial infrastructure.
You may also be interested in...
As Advanz completes its deal to acquire Intercept’s ex-US business, the company has confirmed a management change that has seen chief commercial officer Paul Burden leave the company, with the appointment of two new regional CCOs.
Generics Bulletin Podcast – GenBioPro v. West Virginia: The Future Of Mifepristone In America, With Professor Greer Donley
Generics Bulletin spoke to University of Pittsburgh School of Law professor Greer Donley, a specialist in reproductive law, about generic mifepristone manufacturer GenBioPro’s lawsuit challenging West Virginia’s state-level restrictions on medical abortion access and its potential wider relevance for the industry.
In Vivo reporter Chloe Kent caught up with Life Arc CEO Melanie Lee to discuss the power of philanthropy in early-stage biopharma funding.